Evidence – Ayurved Healing

The Parting Research Gift: 20 Studies Every Ayurvedic User Should Read

Dr. Meera Iyer — Fri, 10 Apr 2026 22:15:02 +0000

This reading list presents twenty verified papers relevant to Ayurvedic herbs, formulations, yoga, and meditation. It includes randomized trials, reviews, meta-analyses, and laboratory research. Each result applies only to the tested preparation, dose, population, comparator, and outcome.

The papers are starting points for critical reading, not proof that every traditional use or commercial product is effective. Full methods, adverse-event reporting, study limitations, and funding should be reviewed before applying any finding.

Stress, Pain, and Inflammation

These studies examine standardized ashwagandha, curcumin, and Boswellia preparations; their findings should not be generalized to unlike products.

Study 1: Ashwagandha for Stress

Lopresti et al., Medicine, 2019. A double-blind RCT of 60 adults found that 240 mg/day of standardized Withania somnifera extract for 60 days improved selected anxiety measures and reduced morning cortisol versus placebo. PMID 31517876.

Study 2: Ashwagandha for Anxiety

Pratte et al., Journal of Alternative and Complementary Medicine, 2014. This systematic review found five generally favorable human trials, but heterogeneity and risk of bias prevented firm conclusions. PMID 25405876.

Study 3: Turmeric or Curcumin for Arthritis

Daily et al., Journal of Medicinal Food, 2016. A review and meta-analysis of eight RCTs found improved arthritis pain with turmeric extracts or curcumin; pooled pain scores did not differ significantly from conventional pain medicines. PMID 27533649.

Study 4: Boswellia for Osteoarthritis

Yu et al., BMC Complementary Medicine and Therapies, 2020. Seven RCTs indicated improvements in osteoarthritis pain, stiffness, and physical function, although the studies and extracts were heterogeneous. PMID 32680575.

Study 5: Curcuminoids and C-Reactive Protein

Sahebkar, Phytotherapy Research, 2014. A six-trial meta-analysis found lower CRP with curcuminoids versus placebo, especially in longer trials using bioavailability-enhanced preparations. PMID 23922235.

Triphala, Bioavailability, and Cognition

This group separates clinical findings from narrative or pharmacokinetic evidence and avoids treating mechanistic results as therapeutic proof.

Study 6: Triphala and the Gut Microbiome

Peterson et al., Journal of Alternative and Complementary Medicine, 2017. This narrative review discusses possible interactions between Triphala polyphenols and gut microorganisms; it is not a human microbiome trial. PMID 28696777.

Study 7: Triphala Mouthwash

Naiktari et al., Journal of Periodontal & Implant Science, 2014. In 120 hospitalized patients, Triphala and 0.2% chlorhexidine mouthwashes both reduced plaque and gingival indices over 15 days, with no significant difference between the active groups. PMID 24921057.

Study 8: Piperine and Curcumin

Shoba et al., Planta Medica, 1998. In a small single-dose human experiment, 20 mg piperine given with 2 g curcumin markedly increased measured curcumin bioavailability; clinical benefit was not tested. PMID 9619120.

Study 9: Bacopa Meta-Analysis

Kongkeaw et al., Journal of Ethnopharmacology, 2014. Nine placebo-controlled trials involving 518 participants suggested cognitive benefit, most consistently for speed of attention. PMID 24252493.

Study 10: Bacopa in Older Adults

Calabrese et al., Journal of Alternative and Complementary Medicine, 2008. In 54 adults aged 65 or older, 300 mg/day standardized Bacopa monnieri extract for 12 weeks improved delayed word recall and selected outcomes versus placebo. PMID 18611150.

Formulations and Immune Research

Clinical formulation trials and laboratory immunology studies answer different questions and should not be presented as interchangeable evidence.

Study 11: AYUSH-64 and COVID-19

Chopra et al., PLOS ONE, 2023. An open-label, assessor-blinded multicenter RCT of 140 hospitalized adults reported faster clinical recovery when AYUSH-64 was added to standard care; further validation was recommended. PMID 36928877.

Study 12: Guduchi Compounds

Sharma et al., Journal of Ethnopharmacology, 2012. Compounds isolated from Tinospora cordifolia showed immunomodulatory activity in experimental assays. This was mechanistic research, not a human infection trial. PMID 22472109.

Reproductive and Menopausal Health

These relatively small trials are product-specific and do not replace medical evaluation of infertility, hormonal symptoms, or pregnancy-related illness.

Study 13: Ashwagandha in Oligospermia

Ambiye et al., Evidence-Based Complementary and Alternative Medicine, 2013. A placebo-controlled pilot RCT of 46 men found that 675 mg/day standardized root extract for 90 days improved sperm concentration, semen volume, and motility. PMID 24371462.

Study 14: Purified Shilajit and Androgens

Pandit et al., Andrologia, 2016. In healthy men aged 45–55, purified Shilajit at 250 mg twice daily for 90 days increased total testosterone, free testosterone, and DHEAS versus placebo. PMID 26395129.

Study 15: Shatavari for Menopausal Symptoms

Gudise et al., Cureus, 2024. A double-blind multicenter RCT in 70 women reported improved menopausal symptom and quality-of-life measures after 60 days of standardized Asparagus racemosus root extract. PMID 38725785.

Study 16: Ginger for Pregnancy Nausea

Viljoen et al., Nutrition Journal, 2014. A meta-analysis of 12 RCTs involving 1,278 pregnant participants found improved nausea with ginger versus placebo; effects on vomiting were less clear. PMID 24642205.

Cardiac, Mood, Yoga, and Meditation Research

The final studies range from a very small cardiac trial to broader evidence syntheses, so their strength and clinical relevance differ substantially.

Study 17: Arjuna in Heart Failure

Bharani et al., International Journal of Cardiology, 1995. A placebo-controlled crossover study in 12 patients with severe refractory heart failure reported improvements in symptoms, functional class, and selected cardiac measures. PMID 7649665.

Study 18: Curcumin in Major Depression

Lopresti et al., Journal of Affective Disorders, 2014. In 56 participants, 1,000 mg/day curcumin did not separate from placebo across the full eight weeks, although benefits appeared during weeks four to eight and in an atypical-depression subgroup. PMID 25046624.

Study 19: Yoga for Low Back Pain

Wieland et al., Cochrane Database of Systematic Reviews, 2017. Twelve trials involving 1,080 participants provided low-to-moderate-certainty evidence of small-to-moderate functional improvement versus no exercise. PMID 28076926.

Study 20: Mindfulness and Telomerase

Schutte and Malouff, Psychoneuroendocrinology, 2014. Four randomized trials totaling 190 participants showed a moderate pooled increase in telomerase activity; telomere length, longevity, and reversal of aging were not established. PMID 24636500.

Using the Evidence Responsibly

Read beyond the abstract and distinguish statistical significance from clinical importance. Small samples, short follow-up, extract differences, and selective outcomes can limit how widely a result applies.

Disclaimer: This list is educational and does not provide individualized treatment advice. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using herbs or formulations, especially during pregnancy, for infertility, or for psychiatric, cardiac, or other serious conditions.

References

The Complete Triphala Evidence Guide: Everything Research Has Validated

Dr. Meera Iyer — Tue, 10 Mar 2026 16:05:06 +0000

Triphala is a classical Ayurvedic three-fruit formulation made from the dried fruit material of Amalaki (Phyllanthus emblica; synonym Emblica officinalis), Bibhitaki (Terminalia bellirica), and Haritaki (Terminalia chebula). The equal-part powdered preparation is described in the Ayurvedic Formulary of India. Classical texts also contain Triphala-based rasayana regimens with particular proportions and adjuvants, so those regimens should not automatically be treated as identical to every modern capsule, extract, or commercial powder.

The modern evidence is uneven. Human trials are available for oral hygiene, body-weight outcomes, short-term safety, and some metabolic measures, but many broader claims rest mainly on laboratory or animal experiments. Formulation, dose, and study population vary substantially, limiting direct comparison.

Classical Ayurvedic Position

Triphala has an established place in Ayurvedic rasayana practice. The Charaka Samhita, Chikitsa Sthana, Rasayana Adhyaya, includes Triphala-based regimens in its discussion of rejuvenative care. This classical use concerns an individualized regimen involving the fruits and specified vehicles; it is not a modern guarantee that a fixed commercial dose will prevent or treat every condition associated with ageing.

In practical Ayurveda, Triphala is commonly selected when bowel regularity, digestion, and long-term constitutional support are being considered. Amount, timing, vehicle, and duration depend on digestive strength, stool pattern, age, illness, and the wider treatment plan. A qualified Ayurvedic practitioner should distinguish a gentle supportive use from therapeutic purgation or treatment of a diagnosed gastrointestinal disorder.

Digestive Regulation: Traditional Use with Limited Clinical Confirmation

Digestive and bowel-regulating use is the best-known traditional application. A 45-day clinical study involving 160 people compared three Triphala preparations and reported improvements in stool amount, frequency, consistency, flatulence, belching, abdominal pain, and related symptom scores. The study used subjective scoring and did not provide the type of placebo-controlled design expected for a definitive efficacy claim.

Reviews of Triphala in functional gastrointestinal disorders describe mild laxative activity and possible effects on motility, mucosal function, and intestinal microorganisms. Much of the mechanistic work, however, comes from extracts, isolated constituents, laboratory systems, or animal models. These findings do not establish that Triphala is non-habit-forming, that it cannot cause rebound symptoms, or that it is categorically different from all stimulant laxatives.

For occasional constipation, Triphala may be considered only after basic causes such as inadequate fluid or fibre intake, medication effects, painful fissures, thyroid disease, or other bowel disorders have been considered. Persistent constipation, bleeding, vomiting, unexplained weight loss, anaemia, severe pain, or sudden bowel changes require medical assessment.

Antioxidant Activity: Strongest in Laboratory Studies

Triphala and its three constituent fruits contain polyphenolic compounds, including gallic acid, ellagic acid, chebulagic acid, and chebulinic acid. A 2005 laboratory study found that Triphala’s constituents displayed free-radical reactions and antioxidant activity under different experimental conditions. This supports chemical antioxidant potential, but an in-vitro assay does not by itself demonstrate prevention or treatment of disease in people.

A 2016 cell study examined Triphala extract in human dermal fibroblasts and keratinocytes. The extract protected cultured cells against hydrogen-peroxide-related oxidative injury and reduced markers of DNA damage and cellular senescence under the tested conditions. The experiment did not demonstrate a clinical anti-ageing effect, did not measure outcomes in people, and was not a trial of oral Triphala for skin disease.

Evidence level: Consistent laboratory antioxidant activity is documented. Human biomarker and clinical-outcome data remain too limited and heterogeneous to support broad claims that routine Triphala supplementation prevents oxidative-stress-related disease.

Anti-Inflammatory Effects: Preclinical

In cultured macrophages, Triphala extract reduced the expression or production of inflammatory mediators including TNF-alpha, IL-1beta, IL-6, nitric oxide, iNOS, and COX-2. The same publication reported anti-inflammatory effects in an adjuvant-induced arthritis model in rats, associated with modulation of NF-kappaB signalling. These are mechanistic and animal findings rather than proof of benefit for human rheumatoid arthritis or osteoarthritis.

Triphala Guggulu is a separate multi-ingredient Ayurvedic formulation containing Triphala and processed Guggulu. Results obtained with Triphala Guggulu cannot be attributed to Triphala alone. Triphala should not replace diagnosis, disease-modifying treatment, analgesic planning, or physiotherapy for inflammatory joint disease.

Antimicrobial and Oral-Health Applications

Extracts of Triphala and its fruits have inhibited several microorganisms in laboratory experiments, with results depending on the solvent, concentration, organism, and test method. Such findings do not make oral Triphala a systemic antibiotic or antifungal treatment. The most clinically relevant antimicrobial application studied so far is its use as a mouth rinse for plaque and gingival inflammation.

In a 2014 double-blind randomized multicentre trial, 120 hospitalized patients were divided among distilled-water, 0.2% chlorhexidine, and Triphala mouth-rinse groups. Participants used 10 mL for one minute twice daily for two weeks. Triphala and chlorhexidine both reduced plaque and gingival index scores compared with the water control, and the trial found no significant efficacy difference between the two active rinses over that short period.

A later systematic review found Triphala mouthwashes more effective than placebo for gingivitis and found no statistically significant difference between Triphala and chlorhexidine across the included studies. Studies varied in concentration, duration, population, and quality. A standardized dental product may therefore be a possible adjunct to brushing and professional care, but it should not be presented as a proven replacement for chlorhexidine in every clinical situation.

Weight and Metabolic Outcomes: Preliminary and Heterogeneous

A 2012 double-blind randomized placebo-controlled trial enrolled 62 participants with obesity. The tested product was an Itrifal Saghir confection made from equal portions of the three fruits with almond oil and honey, taken as 5 g twice daily for 12 weeks. Compared with placebo, the intervention produced a reported between-group difference of 4.82 kg in weight loss, together with reductions in waist and hip circumference. This result applies to that specific confection and study population, not automatically to ordinary Triphala tablets or powder.

A 2021 systematic review of clinical studies reported favourable changes in some lipid, glucose, weight, body-mass-index, and waist-circumference outcomes, while also emphasizing the need for larger, well-designed randomized trials. The included studies differed in formulations, doses, populations, and methods. Triphala is therefore not an established stand-alone treatment for obesity, diabetes, or dyslipidaemia and should not displace nutrition, activity, sleep, behavioural care, or prescribed medication.

Anticancer Findings: Laboratory and Animal Research Only

Triphala extracts have been examined in cancer-cell and animal models. A 2015 study found that a methanol extract suppressed proliferation and induced apoptosis-related changes in human colon cancer stem cells and HCT116 colon cancer cells, including changes in c-Myc, cyclin D1, Bax, and Bcl-2-related signalling. The authors called for further in-vivo investigation.

Human anticancer efficacy has not been established in clinical trials. Triphala must not be promoted as a cancer treatment, a substitute for surgery, radiotherapy, chemotherapy, immunotherapy, endocrine therapy, or evidence-based prevention. A person with cancer should discuss every herbal product with the oncology team because supplements may affect symptoms, laboratory tests, treatment tolerance, or drug metabolism.

Dose and Formulation

There is no single clinically validated Triphala dose for all goals. Crude powder, tablets, aqueous extracts, alcoholic extracts, confections, and mouth rinses are not dose-equivalent. The amounts below describe studied exposures or safe-use boundaries, not universal prescriptions.

Form or purpose	Documented exposure	How to interpret it
Traditional powder or tablets	Product- and practitioner-specific	Follow a quality-controlled label and individualized professional advice; tablet counts cannot be converted reliably without knowing extract strength.
Aqueous extract safety study	2,500 mg daily for 4 weeks	Studied in a small group of healthy adults for short-term safety; not proof of long-term safety or efficacy.
Weight trial confection	5 g twice daily for 12 weeks	A honey-and-almond-oil confection used under trial conditions; not a general weight-loss recommendation.
Clinical mouth rinse	10 mL twice daily for 2 weeks in one trial	Use only a standardized oral product as directed by a dentist or its validated label; do not swallow.
Eye application	Home-prepared infusions are unsuitable	Anything placed in the eye must be sterile; powdered-herb infusions should not be used as eye drops or eye wash.

Safety Profile

A small human safety study gave 2,500 mg per day of a standardized aqueous extract to healthy volunteers for four weeks and reported no serious adverse effects. Long-duration animal toxicology has also been reassuring at the tested doses. These findings support short-term tolerability of specified preparations, but they do not justify the claim that every Triphala product is proven safe for indefinite daily use.

Possible dose-related effects include loose stools, urgency, abdominal discomfort, or cramping. Stop use and seek advice if diarrhoea is persistent, dehydration develops, symptoms worsen, or an allergic reaction occurs. Safety during pregnancy, breastfeeding, and childhood has not been adequately established, so routine unsupervised use in these groups is inappropriate.

Laboratory and animal studies indicate that Triphala can influence some cytochrome P450 enzymes and drug transport processes, while direct clinically significant interactions in humans remain insufficiently characterized. People taking prescription medicines—especially drugs with a narrow therapeutic range or medicines for diabetes, blood pressure, clotting, seizures, transplantation, or cancer—should obtain advice from a physician or pharmacist before use.

The Bottom Line

Triphala is an authentic classical Ayurvedic formulation with a prominent rasayana and digestive role. Its most persuasive human data concern short-term oral-health use, while digestive benefits are supported by tradition and limited clinical studies. Antioxidant, anti-inflammatory, antimicrobial, and anticancer mechanisms are mainly laboratory or animal findings, and weight-related results come from small, heterogeneous trials.

The formulation should be valued without turning preclinical findings into treatment promises. Preparation, dose, and patient context matter. Consult a qualified Ayurvedic practitioner and healthcare provider before using Triphala for a chronic condition, during pregnancy or breastfeeding, in children, alongside prescription medicines, or as part of cancer care.

References

Ashwagandha: The Most Complete Research Summary for Evidence-Based Practitioners

Dr. Meera Iyer — Mon, 09 Mar 2026 14:13:02 +0000

Ashwagandha (Withania somnifera (L.) Dunal) is promoted for stress, anxiety, sleep, cognition, hormones, thyroid function, and exercise performance. The evidence is uneven: most trials are small, short, and tied to a specific preparation, so findings from one extract or powder cannot automatically be transferred to another product.

The Ayurvedic Pharmacopoeia of India identifies Aśvagandhā as the dried mature root. It lists tikta and kaṣāya rasa, laghu guna, uṣṇa vīrya, madhura vipāka, and the actions rasāyana, vātakaphāpaha, balya, and vājīkaraṇa. Its powder dose is 3–6 g. This is not equivalent to the milligram dose of a concentrated extract, and classical properties should not be converted directly into claims for modern diagnosed diseases.

Moderate Evidence: Stress and Cortisol Reduction

Stress is the best-supported modern use, but “strong evidence” overstates certainty. A 2022 meta-analysis in Phytotherapy Research included 12 randomized-trial papers with 1,002 participants. Ashwagandha reduced stress (standardized mean difference −1.75; 95% CI −2.29 to −1.22) and anxiety (−1.55; 95% CI −2.37 to −0.74), but heterogeneity was high and certainty was rated low.

A 2021 review covered seven trials involving 491 adults treated for six to eight weeks. Studies used root extracts, root-and-leaf extracts, an unspecified extract, or root granules; extract doses ranged from 240 to 1,250 mg/day, while the granules equaled 6 g/day of root powder. Most reported improved perceived stress, and several reported lower cortisol, but the preparation differences prevent a universal dose recommendation.

In the Salve trial, 60 stressed adults received aqueous root extract at 125 mg twice daily, 300 mg twice daily, or placebo for eight weeks. Both active regimens improved stress measures and reduced cortisol. Confidence level: Moderate because samples were small, follow-up was short, and products and methods varied.

Limited-Moderate Evidence: Anxiety Reduction

Anxiety scores often improve in stress trials, but many participants had self-reported stress or mild symptoms rather than a rigorously diagnosed anxiety disorder. NCCIH states that some preparations may help stress and insomnia while evidence for anxiety remains unclear.

An international psychiatric taskforce provisionally discussed 300–600 mg/day of standardized root extract for generalized anxiety disorder while emphasizing that stronger evidence is needed. Ashwagandha should not replace psychotherapy, psychiatric assessment, or prescribed treatment. Confidence level: Limited to moderate.

Moderate Evidence: Sleep Quality

A 2021 meta-analysis included five randomized trials with 400 participants and found a small but significant overall sleep benefit (standardized mean difference −0.59; 95% CI −0.75 to −0.42). Effects were more prominent in adults with insomnia, at doses of at least 600 mg/day, and when treatment lasted at least eight weeks.

Four trials used KSM-66 root extract and one used Shoden root-and-leaf extract. Outcomes included sleep quantity, quality, latency, efficiency, and alertness on rising. Certain extracts may improve sleep, but they are not proven substitutes for evaluating chronic insomnia, sleep apnea, depression, medication effects, or thyroid disease. Confidence level: Moderate.

Limited-Moderate Evidence: Muscle Strength and Recovery

The 2015 Wankhede trial enrolled 57 healthy men aged 18–50 with little resistance-training experience. Participants received 300 mg of root extract twice daily or placebo during eight weeks of training. Mean bench-press strength rose by 46.0 kg with ashwagandha and 26.4 kg with placebo; leg-extension strength and selected muscle-size measures also improved more in the active group.

The trial additionally reported differences in testosterone, body-fat percentage, and serum creatine kinase. A 2026 meta-analysis pooled four strength studies involving 223 participants and found a favorable effect, but certainty for muscle strength was low and heterogeneity was moderate; pooled body weight and body-fat effects were not significant.

Confidence level: Limited to moderate; the findings do not justify broad claims for all athletes or preparations.

Limited Evidence: Testosterone and Male Fertility

In a 2019 crossover trial, overweight men aged 40–70 with mild fatigue received standardized Shoden extract for eight weeks. Compared with placebo, DHEA-S increased by 18% more and testosterone by 14.7% more.

The study found no significant between-group differences in fatigue, vigor, sexual well-being, psychological well-being, cortisol, or estradiol. A 2026 meta-analysis of seven testosterone studies involving 488 participants found a small pooled increase, but populations and preparations differed. NCCIH describes testosterone and sperm-quality evidence as limited.

Ashwagandha is not an established treatment for hypogonadism, erectile dysfunction, or infertility, and results from stressed, overweight, training, or subfertile populations should not be generalized to every healthy man. Confidence level: Limited and population-specific.

Preliminary Evidence and Caution: Thyroid Function

A double-blind trial in 50 adults with subclinical hypothyroidism compared 300 mg of root extract twice daily with placebo for eight weeks. TSH decreased and T3 and T4 increased in the active group. One small trial does not establish treatment for overt hypothyroidism, Hashimoto disease, hyperthyroidism, thyroid nodules, or patients stabilized on thyroid medicine.

NIH sources also describe thyroid-hormone changes and case reports of thyrotoxicosis that improved after ashwagandha was stopped. People with thyroid disease, abnormal tests, or thyroid medication should not use it without clinician supervision. Confidence level: Preliminary for benefit, with a meaningful safety signal.

Limited-Moderate Evidence: Cognition and Memory

A 2017 pilot trial randomized 50 adults with mild cognitive impairment to 300 mg of root extract twice daily or placebo for eight weeks. The active group improved on tests of immediate and general memory, executive function, sustained attention, and information-processing speed. This does not establish prevention or treatment of dementia or another neurological disease.

A 2026 meta-analysis included 20 studies with 1,249 participants across cognitive and physical outcomes. Pooled results favored ashwagandha for memory and attention or processing speed; certainty was moderate for these outcomes and low for executive function. Global cognition came from one study and was rated very low certainty. Confidence level: Limited to moderate for selected test outcomes.

Insufficient Evidence: Blood Sugar and Inflammation

A 2020 diabetes review found only five clinical studies alongside much more laboratory and animal research and concluded that human evidence was not robust enough for therapeutic use. Small studies have also measured inflammatory or oxidative-stress biomarkers, but biomarker changes do not prove treatment of inflammatory disease. NCCIH considers evidence insufficient for diabetes and most other promoted conditions.

Root Powder and Proprietary Extracts Are Not Interchangeable

“Ashwagandha” is not one uniform intervention. The pharmacopoeial drug is dried mature root; KSM-66 is a root extract; and Sensoril and Shoden are root-and-leaf extracts used at different doses and standardizations. Evidence belongs first to the exact preparation and regimen studied.

Preparation	Verified distinction	Main limitation
API root powder	Dried mature root; dose 3–6 g	Not directly convertible to extract milligrams
KSM-66	Root extract used in multiple trials	Results apply to comparable regimens
Sensoril	Root-and-leaf extract used in stress studies	Not identical to the official root drug
Shoden	Concentrated root-and-leaf extract	Lower mass does not prove superiority
Unspecified extract	Plant part or standardization may be unclear	Difficult to match reliably to research

A stated withanolide percentage is not a universal potency scale. Plant part, extraction, marker definition, dose, accompanying ingredients, duration, product quality, and patient population all affect whether research applies to a commercial supplement.

Safety Summary

Ashwagandha may be reasonably tolerated for short-term use, generally up to about three months, but long-term safety is unknown. Reported effects include drowsiness, stomach upset, diarrhea, and vomiting.

Rare clinically apparent liver injury has been reported. LiverTox describes typical onset two to twelve weeks after starting ashwagandha, usually with cholestatic or mixed injury, jaundice, and itching. Most cases improve after stopping, but liver failure, transplantation, and deaths have occurred, particularly with pre-existing liver disease or cirrhosis. Avoid use in cirrhosis or advanced chronic liver disease and avoid rechallenge after suspected injury.

Important cautions and possible interactions include:

Pregnancy and breastfeeding: NCCIH advises avoidance.
Thyroid disorders or thyroid medicine: Hormone changes may interfere with treatment.
Sedatives and anticonvulsants: Additive nervous-system effects are possible.
Diabetes and blood-pressure medicines: Additive glucose- or pressure-lowering effects are possible.
Immunosuppressants or autoimmune disorders: Potential immune effects require caution.
Surgery: NCCIH does not recommend use when surgery is approaching.
Hormone-sensitive prostate cancer: Avoid use because testosterone may increase.

Stop use and seek medical assessment for jaundice, dark urine, severe itching, persistent vomiting, unusual fatigue, upper-abdominal discomfort, palpitations, tremor, or marked heat intolerance.

Dosage by Indication: Evidence Reference

No universal therapeutic dose is established. These are selected study regimens and the pharmacopoeial powder dose, not interchangeable prescriptions.

Outcome studied	Example regimen	Limitation
Perceived stress	125 or 300 mg aqueous root extract twice daily for 8 weeks	One product-specific trial
Stress/anxiety studies	Various extracts, 240–1,250 mg/day for 6–8 weeks	Preparations and scales varied
Sleep	Product-specific extracts; stronger subgroup signal at ≥600 mg/day and ≥8 weeks	Not a universal dose
Resistance training	300 mg root extract twice daily for 8 weeks	Key trial involved inexperienced men
Cognition	300 mg root extract twice daily for 8 weeks	Small pilot; other trials used other products
Subclinical hypothyroidism	300 mg root extract twice daily for 8 weeks	Single trial plus thyroid risk
Traditional root powder	API: 3–6 g	Not an extract conversion

The Bottom Line for Practitioners

The most defensible conclusion is that certain ashwagandha preparations may reduce perceived stress and modestly improve sleep during short-term use. Evidence for diagnosed anxiety disorders is less secure. Muscle strength, testosterone, cognition, male fertility, and thyroid effects remain limited, product-specific, or population-specific; evidence for treating diabetes and inflammatory disease is insufficient.

Responsible practice requires identifying the plant part and preparation, matching claims and doses to the tested product, and not assuming that short trials establish indefinite safety. Screen for pregnancy, breastfeeding, liver or thyroid disease, autoimmune disorders, surgery, hormone-sensitive prostate cancer, and interacting medicines. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before medical use or use with prescription treatment.

This article is educational and does not diagnose, treat, or replace individualized care. Persistent anxiety, insomnia, fatigue, fertility concerns, cognitive symptoms, or abnormal thyroid, liver, glucose, or hormone results require professional assessment.